Quidel (QDEL) Getting Somewhat Favorable News Coverage, Report Shows

News articles about Quidel (NASDAQ:QDEL) have trended somewhat positive on Thursday, Accern Sentiment reports. The research group scores the sentiment of media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Quidel earned a media sentiment score of 0.06 on Accern’s scale. Accern also gave news stories about the company an impact score of 45.5261147132922 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

These are some of the news stories that may have effected Accern Sentiment’s scoring:

QDEL has been the topic of a number of recent analyst reports. Zacks Investment Research downgraded shares of Quidel from a “buy” rating to a “hold” rating in a research note on Tuesday, November 7th. Barclays raised their target price on shares of Quidel from $45.00 to $49.00 and gave the stock an “overweight” rating in a report on Thursday, November 2nd. Raymond James Financial restated a “buy” rating and issued a $47.00 target price (up previously from $41.00) on shares of Quidel in a report on Tuesday, September 19th. Canaccord Genuity reiterated a “buy” rating and issued a $48.00 price target on shares of Quidel in a report on Wednesday, October 25th. Finally, Piper Jaffray Companies reiterated a “buy” rating and issued a $50.00 price target on shares of Quidel in a report on Friday, November 3rd. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $48.80.

Quidel (QDEL) opened at $39.80 on Thursday. The company has a current ratio of 6.28, a quick ratio of 5.68 and a debt-to-equity ratio of 0.70. Quidel has a 52 week low of $18.25 and a 52 week high of $45.55.

Quidel (NASDAQ:QDEL) last announced its quarterly earnings data on Wednesday, November 1st. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.05 by ($0.21). The company had revenue of $50.89 million for the quarter, compared to the consensus estimate of $50.47 million. Quidel had a negative net margin of 2.33% and a negative return on equity of 2.36%. The company’s revenue was up 3.1% compared to the same quarter last year. During the same quarter last year, the firm posted $0.10 earnings per share. research analysts predict that Quidel will post 0.6 earnings per share for the current fiscal year.

In other Quidel news, CEO Douglas C. Bryant sold 12,000 shares of the company’s stock in a transaction that occurred on Thursday, September 28th. The stock was sold at an average price of $42.86, for a total value of $514,320.00. Following the completion of the transaction, the chief executive officer now directly owns 296,493 shares in the company, valued at approximately $12,707,689.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Werner Kroll sold 7,565 shares of the company’s stock in a transaction that occurred on Monday, November 6th. The stock was sold at an average price of $39.50, for a total value of $298,817.50. Following the completion of the transaction, the senior vice president now owns 10,261 shares of the company’s stock, valued at $405,309.50. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 172,311 shares of company stock valued at $6,953,215. 22.00% of the stock is currently owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: This story was first published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this story on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.com-unik.info/2017/12/07/quidel-qdel-getting-somewhat-favorable-news-coverage-report-shows.html.

About Quidel

Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: immunoassays, molecular assays, virology and specialty products. The Company sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers.

Insider Buying and Selling by Quarter for Quidel (NASDAQ:QDEL)

What are top analysts saying about Quidel Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Quidel Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit